Recently, Sino Biopharm announces that the Category 1 innovative drug “TQC2938” injection developed by the Group has been approved by the National Medical Products Administration of the People's Republic of China, to commence clinical trials for the treatment of moderate to severe asthma.
TQC2938 is a humanised IgG2 monoclonal antibody targeting ST2 (interleukin-33 (IL-33) receptor) and belongs to therapeutic biological product Category 1. TQC2938 specifically binds to human ST2, blocking its interaction with IL-33 ligands, blocking signalling pathway of ST2/IL-33, reducing the production of downstream Th2 cytokines (IL-4, IL-5, IL-13, etc.) and reducing the level of eosinophils and other inflammatory cells, thereby reducing the occurrence of asthma and improving patients’ quality of life. Pre-clinical animal efficacy trials have shown that the candidate molecules can significantly improve disease symptoms.